News

Published on 4 May 2024 on Insider Monkey via Yahoo Finance

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript


Article preview image

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024

Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72. RARE isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon, and welcome to the Ultragenyx First Quarter 2024 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations. You may begin.

NASDAQ.RARE price evolution
NASDAQ.SAFT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust...

Ultragenyx Pharmaceutical Inc (RARE) reports a 42% year-over-year revenue increase, driven by str...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarte...

Insider Monkey · via Yahoo Finance 1 Nov 2024

Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks...

We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 21 Aug 2024

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx...

Key Insights Ultragenyx Pharmaceutical will host its Annual General Meeting on 18th of JuneCEO Em...

Simply Wall St. · via Yahoo Finance 20 Jun 2024

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

Ultragenyx Pharmaceutical RARE announced positive top-line results from the late-stage study of i...

Zacks via Yahoo Finance 31 May 2024

Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...

Total Revenue: Reported $109 million in Q1 2024, an 8% increase year-over-year, falling short of ...

GuruFocus.com via Yahoo Finance 5 May 2024

Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just released its latest first-quarter report and th...

Simply Wall St. via Yahoo Finance 4 May 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultrage...

Insider Monkey via Yahoo Finance 4 May 2024

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $2.03 per share in the first quarter of 20...

Zacks via Yahoo Finance 3 May 2024

Ultragenyx executive sells shares worth over $15,000 By Investing.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP and Chief Medical Officer, Eric Crombez, has sol...

Investing.com 3 May 2024